Meet our Board of Directors

PathoQuest is led by a board of directors who are seasoned leaders in their respective fields of business. Together, the members of the board of directors help to develop policies and strategies which are implemented by PathoQuest’s executive team.

Benedikt von Braunmühl - Chairman

Mr. Benedikt Von Braunmühl serves as CEO of the Synevo Division at Medicover. Mr. Von Braunmühl has held several high-profile healthcare consulting and advisory roles for companies across the globe supporting geographic expansion, business development, and mergers and acquisitions projects. Mr. Von Braunmühl previously was Senior Vice President – Global Commercial Operations of Qiagen NV, a leading European biotechnology company active in molecular diagnostics and life science markets. Mr. Von Braunmühl started his 25-year healthcare career at AstaMedica and has held various marketing and sales positions in the healthcare industry as well as in investment banking. Mr. Von Braunmühl holds a Bachelor Degree in Business Administration from the Graduate School of Business Administration in Zurich, Switzerland.

Jean-Pascal Beaufret

Mr. Jean-Pascal Beaufret is the Chief Financial Officer of NBN Co. Limited. Mr. Beaufret served as the Chief Financial Officer of Alcatel since 2002. He also served as a General Manager of Electrobanque. In 1999, Mr. Beaufret joined Alcatel as Deputy Chief Financial Officer of the Group. Mr. Beaufret served as an Executive in the Ministry of Finance (Treasury). As Deputy Secretary of the international department, he was responsible for export, credit negotiations and development aid from 1986 to 1988. As Deputy Secretary for monetary affairs, he was in charge of government debt management and financial industry regulation from 1988 to 1994. He served as Chief Financial Officer of Alcatel Optronics from January 1, 2002. From 1995 to 1997, Mr. Beaufret served as the Chief Financial Officer at Credit Foncier de France. He served as General Manager of the French tax administration office since 1997. Mr. Beaufret serves as Member of Advisory Board at Aurinvest. He has been Vice Chairman at Sequana S.A., since June 27, 2013 and has been its Independent Director since May 21, 2008. He served as Member of Supervisory Board at Portigon AG since August 1, 2002. Mr. Beaufret is a graduate of HEC (Paris Business School) and of the ENA (French National School of Public Administration).

Christiane Honisch, PhD

Dr. Christiane Honisch is currently Head of Global Business Intelligence and Development at Eppendorf AG, a leading Life Science company. She has over 15 years of experience developing markers, assays, software and cutting-edge technology for Life Science applications and infectious disease detection, monitoring and characterization. She was formerly the Director of Microbiology Markets at Illumina, Inc. where she was responsible for the development of the company’s next-generation sequencing microbiology and virology market strategy. Prior to this she was the Director of Infectious Disease Research at Roche Molecular Diagnostics responsible for IVD research and microbial surveillance. Her team received the Roche Innovation Award in 2014. Previously she was a key individual in developing the commercial use of nucleic acid based mass spectrometry for DNA sequencing and microbial analysis at Sequenom, Inc. Dr. Honisch holds a diploma in chemistry and received her Ph.D. in molecular biology and microbiology from the University Carolo-Wilheimina zu Braunschweig, Germany and the German National Center for Biotechnology (GBF) in the field of the diagnosis and typing of tuberculosis.

Thierry Laugel, PhD, MBA

Dr. Thierry Laugel, Ph.D. is a co-Founder and Managing Partner at Kurma Partners since 2009. He was previously Partner at AGF Private Equity, (2006 to 2009) and CDC Innovation (1998 to 2005). Before that, he worked for Flamel Technologies as Project Director for Pharmaceutical R&D (1997-1998) and Fournier Japan, as Coordinator of R&D programmes (1992 – 1996). He has served as Director or Board member in more than 20 companies. Dr. Laugel holds a Pharm.D, a Ph.D. in Pharmacology, and an M.B.A. from INSEAD.